

REMARKS

Claims 1-47 are pending in this application. Applicants herewith cancel claims 37-47 and added new claims 48 and 49. Accordingly, claims 1-36 and 47 and 48 are pending and subject to examination. Applicants maintain that the amendment do not add any new matter. Specifically, claim 48 was added as a generic claim to all the species indicated by the Examiner.

Restriction Requirement

The Examiner has required restriction of claims 1-47 under 35 U.S.C. §121 and §372. More specifically, the Examiner has required restriction to one of the following groups, as described below:

Group I	Claims 1-36, drawn to a method of treatment.
Group II	Claims 37-47, drawn to a composition.

The Examiner has also required the election of one of the following species:

A	Retinoid
B	Growth factor receptor inhibitor
C	A vitamin D analog
D	A chemotherapy agent, and
E	Cancer to be treated

In response, Applicants hereby elect Group I without traverse. In addition, Applicants elect the following species:

Retinoid = 4-oxo-retinol;

Growth factor receptor inhibitor = IRESSA®;

Vitamin D analog = calcitriol;

Chemotherapy agent = cisplatin;


Cancer to be treated = non small cell lung cancer.

Applicants expressly reserve the right to rejoin non-elected species, if the generic claims of Group I are found allowable.

No fee(s) are believed to be due with this response.

Respectfully submitted,

Date: 12/14/07


Charles Achkar
Applicant
7855 Boulevard East #22i
North Bergen, NJ 07047
(201) 724-7484 (Telephone)
(201) 295-1373 (Facsimile)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 14, 2007.

Signature 
Diane M. Tornioli